ADVFN Logo
Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

IRWD Ironwood Pharmaceuticals Inc

8.71
0.09 (1.04%)
Mar 28 2024 - Closed
Delayed by 15 minutes

Period:

Draw Mode:

Volume 2,699,382
Bid Price 8.65
Ask Price 8.79
News (1)
Day High 9.005

Low
8.075

52 Week Range

High
15.70

Day Low 8.59
Company Name Stock Ticker Symbol Market Type
Ironwood Pharmaceuticals Inc IRWD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.09 1.04% 8.71 17:51:15
Open Price Low Price High Price Close Price Prev Close
8.70 8.59 9.005 8.71 8.62
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
16,974 2,699,382 $ 8.77 $ 23,674,128 - 8.075 - 15.70
Last Trade Time Type Quantity Stock Price Currency
17:39:45 1 $ 8.6313 USD

Ironwood Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
1.36B 156.53M - 442.74M -1B -6.40 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Ironwood Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....


No posts yet, be the first! No IRWD Message Board. Create One! See More Posts on IRWD Message Board See More Message Board Posts

Historical IRWD Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week9.129.238.218.603,209,566-0.41-4.50%
1 Month10.6711.008.219.008,197,005-1.96-18.37%
3 Months12.4315.708.2111.135,070,991-3.72-29.93%
6 Months9.8315.708.2110.773,492,618-1.12-11.39%
1 Year10.7815.708.07510.522,986,232-2.07-19.20%
3 Years10.7715.708.07511.212,471,230-2.06-19.13%
5 Years12.8015.707.9111.002,201,634-4.09-31.95%

Ironwood Pharmaceuticals Description

Ironwood Pharmaceuticals is a specialty and generic drug manufacturing company that operates a human therapeutics segment. The company is focused on advancing innovative product opportunities in areas of large unmet need, including irritable bowel syndrome with constipation, chronic idiopathic constipation, hyperuricemia associated with uncontrolled gout, uncontrolled gastroesophageal reflux disease, and vascular and fibrotic diseases. The company considers collaborative licenses, commercial agreements, and acquisition investment to be potential components of its operational growth strategy for expanding its research, development, manufacturing, and marketing capabilities.

Your Recent History

Delayed Upgrade Clock